Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-25-035059
Filing Date
2025-04-24
Accepted
2025-04-24 16:08:14
Documents
18
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT ea0238624-01.htm   iXBRL DEF 14A 790226
6 GRAPHIC tbarchart_001.jpg GRAPHIC 292613
7 GRAPHIC tbarchart_002.jpg GRAPHIC 273395
  Complete submission text file 0001213900-25-035059.txt   2754512

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE iccc-20250425.xsd EX-101.SCH 12678
3 XBRL DEFINITION FILE iccc-20250425_def.xml EX-101.DEF 7793
4 XBRL LABEL FILE iccc-20250425_lab.xml EX-101.LAB 42639
5 XBRL PRESENTATION FILE iccc-20250425_pre.xml EX-101.PRE 13827
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0238624-01_htm.xml XML 171755
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12934 | Film No.: 25867356
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)